SecProbe.io

Filing text and metadata
Intelligence Terminal Search Probe Scores Topics IPO Watchlist Monthly Activity About API

SEC Company Response from Can-Fite BioPharma Ltd. (CANF) (CIK 0001536196) (CANF) — Feb 7, 2020

Can-Fite BioPharma Ltd. (CANF) (CIK 0001536196)
Date: Feb. 7, 2020 · CIK: 0001536196 · Accession: 0001213900-20-002865

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-236064

Date
February 10, 2020
Author
Chief Operating
Form
CORRESP
Company
Can-Fite BioPharma Ltd. (CANF) (CIK 0001536196)

Letter

Re: Can-Fite BioPharma Ltd.

February 7, 2020

VIA EDGAR

U.S. Securities and Exchange Commission

Division of Corporation Finance

F. Street, N.E.

Washington, DC 20549

Registration Statement on Form F-1 (File No. 333-236064)

Concurrence in Acceleration Request

Ladies and Gentlemen:

H.C. Wainwright & Co., LLC (“Wainwright”), as placement agent for the referenced offering, hereby concurs in the request by Can-Fite BioPharma Ltd. that the effective date of the above-referenced registration statement be accelerated to 9:00 a.m. (Eastern Time), or as soon as practicable thereafter, on February 10, 2020, pursuant to Rule 461 under the Securities Act. Wainwright affirms that it is aware of its obligations under the Securities Act in connection with this offering.

H.C. WAINWRIGHT & CO., LLC

By: /s/ Edward D. Silvera

Name: Edward D. Silvera

Title: Chief Operating Officer

Park Avenue | New York, New York 10022 | 212.356.0500

Security services provided by H.C. Wainwright & Co., LLC | Member: FINRA/SIPC

Show Raw Text
CORRESP
1
filename1.htm

February
7, 2020

VIA
EDGAR

U.S.
Securities and Exchange Commission

Division
of Corporation Finance

100
F. Street, N.E.

Washington,
DC 20549

 Re: Can-Fite
BioPharma Ltd.

Registration
Statement on Form F-1 (File No. 333-236064)

Concurrence
in Acceleration Request

Ladies
and Gentlemen:

H.C.
Wainwright & Co., LLC (“Wainwright”), as placement agent for the referenced offering, hereby concurs
in the request by Can-Fite BioPharma Ltd. that the effective date of the above-referenced registration statement be accelerated
to 9:00 a.m. (Eastern Time), or as soon as practicable thereafter, on February 10, 2020, pursuant to Rule 461 under the Securities
Act. Wainwright affirms that it is aware of its obligations under the Securities Act in connection with this offering.

    H.C.
    WAINWRIGHT & CO., LLC

    By:
    /s/
    Edward D. Silvera

    Name:
    Edward
    D. Silvera

    Title:
    Chief Operating
    Officer

430
Park Avenue | New York, New York 10022 | 212.356.0500

Security
services provided by H.C. Wainwright & Co., LLC | Member: FINRA/SIPC